insights_auto
Why is MVIR down 5.46%?
Dive Deeperchevron_right
MVIR:STO
Medivir AB
SEKÂ 1.59
arrow_downward
-5.46%(-0.092) 1D
Oct 5, 5:29:32 PM GMT+2 · SEK
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for MVIR...
Open
SEKÂ 1.67
High
SEKÂ 1.67
Low
SEKÂ 1.59
Mkt. cap
992.59M
Avg. vol.
1.76M
Volume
2.01M
52-wk high
SEKÂ 2.88
52-wk low
SEKÂ 0.34
EPS
-SEKÂ 0.37
Shares outstanding
624.18M
No. of employees
6
Open
SEKÂ 1.67
High
SEKÂ 1.67
Low
SEKÂ 1.59
Mkt. cap
992.59M
Avg. vol.
1.76M
Volume
2.01M
52-wk high
SEKÂ 2.88
52-wk low
SEKÂ 0.34
EPS
-SEKÂ 0.37
Shares outstanding
624.18M
No. of employees
6
News stories
From web sources and news partners
Bloomberg.com
·
38 minutes ago
S&P 500 Closes In on Record High as Tech Rallies: Markets Wrap
24/7 Wall St.
·
18 minutes ago
3 ETFs Measured From the Same 2005 Starting Line. The Plain S&P 500 Fund Turned $10,000 Into $92,435
Profile
Medivir is a Swedish biotech company. Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies.
Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.
In February 2020, Medivir announced that the company has signed a licensing agreement for Xerclear with Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd. The agreement gives SYB the right to register, manufacture and market the product in China. Wikipedia
About Medivir AB